Intended for healthcare professionals

UEG Week
is Online

Want to receive UEG Week virtual highlights and keep up-to-date with expert opinions?

Click Here

Innovate. Build. Discover.

UC the future – click here to access

A recording of the webinar that took place on 8th October 2020

  • Welcome and introductions
    Dr Alessandra Oortwijn, Galapagos Medical Affairs and
    Dr Séverine Vermeire, KU Leuven, Belgium
  • Gilead and Galapagos' collaboration and commitment to inflammation and IBD
    Dr Mark Genovese, Gilead Inflammation Clinical and Research and
    Onno van de Stolpe, Galapagos CEO
  • UC: why innovation is still essential
    Dr Séverine Vermeire
  • Q&A
    All presenters

This programme is not affiliated with UEG Week

Meet the speakers

Dr Séverine Vermeire

Dr Mark

van de Stolpe

Séverine Vermeire, MD PhD

Full Professor of Medicine

Head of the Department of Chronic Diseases, Metabolism (CHROMETA) at KU Leuven in Belgium

Séverine Vermeire is a professor of medicine and Head of the Department of Chronic Diseases & Metabolism (CHROMETA) at KU Leuven in Belgium.

Dr Vermeire obtained her MD degree at KU Leuven in 1995 and a PhD at the same University in 2001 on “Genetic Polymorphisms and Serologic Markers in Inflammatory Bowel Disease”. She further trained at the Universidad Nacional de Asuncion, Paraguay (1993), at the Wellcome Trust Centre for Human Genetics, University of Oxford (1997-1998) UK and at the Montreal General Hospital (McGill University) in Canada (2000–2001). Since 2003, she is staff member at the Gastroenterology Department of the University Hospitals Leuven and is appointed Full Professor of Medicine at KU Leuven. Dr Vermeire is actively involved as principle investigator in RCTs with new therapeutic compounds and has been lead investigator on several of these programs. Her scientific work has resulted in more than 500 peer-reviewed articles so far and focuses on the role of the microbiome and genetic susceptibility in IBD and on identifying predictive signatures of treatment response. Dr Vermeire participated in the International iCHOM consortium on development of Patient-Centered Outcomes for Inflammatory Bowel Disease.

Séverine Vermeire was President of the European Crohn’s and Colitis Organisation (ECCO) from 2014-2016 and of the Belgian IBD Research & Development (BIRD) Group from 2011-2013.

Mark C. Genovese, MD

SVP for Inflammation Clinical Research at Gilead Sciences

Mark C. Genovese, MD, is the SVP for Inflammation Clinical Research at Gilead Sciences. He oversees all clinical research endeavors in the areas of Rheumatology, Pulmonary, GI, Liver, Kidney, and Male Health at Gilead Sciences. He is the James W. Raitt Professor of Medicine-Emeritus and is the former Clinical Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center from 1998-2020.

He received his bachelor's degree from the University of Notre Dame and his medical degree from the Johns Hopkins University School of Medicine. He completed an internship, residency, and chief residency in the Department of Medicine at Stanford University. He remained at Stanford as a fellow in the Division of Immunology and Rheumatology and subsequently joined the faculty in the same division serving as the Clinical chief. Dr Genovese led a patient oriented clinical research program that was focused on translational medicine in autoimmune diseases. He designed and led numerous investigator-initiated studies and international multi-center trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease and arthritis. In addition, he collaborated with other investigators on studies of biomarkers and surrogates associated with disease progression and response to therapy in various autoimmune diseases and arthritis. Dr Genovese previously served as Director of the Center for Clinical Investigation at Stanford University.

He is an author of over 200 peer-reviewed articles, editor on the 7th edition of Kelley’s Textbook of Rheumatology. He is the recipient of the 2008 American College of Rheumatology Henry Kunkel award, and is the Emeritus James W. Raitt Endowed Professor of Medicine at Stanford.

Onno van de Stolpe

CEO and Founder of Galapagos NV

Onno van de Stolpe founded Galapagos in 1999 and has served as Chief Executive Officer from 1999 to the present.

From 1998 to 1999, he was the Managing Director of Genomics at IntroGene (later Crucell, which was acquired by Johnson & Johnson in 2011). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe. He established the European headquarters after joining Molecular Probes, Inc. in the United States. Previously, he worked for The Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotechnology and medical device companies to locate in the Netherlands. Mr. Van de Stolpe started his career as Manager of Business Development at MOGEN International in Leiden. He received an MSc degree from Wageningen University.

Symposium, click here to access

Ulcerative colitis: Today, tomorrow and the future
A recording of the Gilead and Galapagos symposium that took place on 12th October 2020

Professors Laurent Peyrin-Biroulet (Nancy University Hospital, France), Silvio Danese (Humanitas University, Milan, Italy) and Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, NY, USA) will present an overview of the evolving treatment landscape in ulcerative colitis (UC). While the field has seen great progress over the last 20 years, patients with UC still face a considerable disease burden, which cannot currently be managed reliably with approved therapies. Professor Colombel will review the state of the field today, before Professor Danese presents the latest data from the drug pipeline in UC, including the data from the Phase 3 SELECTION trial of filgotinib in UC. Professor Peyrin-Biroulet will look to the distant future of UC treatment before the panel takes questions from the audience.
Meet the speakers

Professor Laurent Peyrin-Biroulet

Silvio Danese

Jean-Frederic Colombel

Laurent Peyrin-Biroulet, MD PhD

Full Professor of Medicine

IBD unit, Inserm U1256 NGERE, Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandœuvre-lès-Nancy, France

Laurent Peyrin-Biroulet is a professor of medicine and head of the Inflammatory Bowel Disease (IBD) unit (Inserm U1256 NGERE) at the University Hospital of Nancy in France. Upon receiving his medical degree and PhD, he undertook a postdoctoral fellowship at the IBD Centre in Lille, France in 2007, before taking a research position at the Mayo Clinic in Rochester, MN, USA (2008–2009).

Professor Peyrin-Biroulet is President of the Group for Therapeutic Studies of Inflammatory Disorders of the Digestive Tract (GETAID) and past-President of the Scientific Committee of the French association of IBD patients, Association François Aupetit (AFA). He is past-Chair of the IBD Committee of the French Society of Digestive Endoscopy (SFED) and past-Chair of the Clinical Trials Task Force at the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Professor Peyrin-Biroulet was a member of the United European Gastroenterology Federation (UEGF) Scientific Committee (2011–2014). Currently he is the President Elect of the European Crohn’s & Colitis Organisation (ECCO) and the Scientific Secretary of IOIBD. Professor Peyrin-Biroulet was the coordinator for the development of the first disability index for IBD and of the treat-to-target (Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE]) recommendations. He proposed the first definitions of early Crohn’s disease and of disease severity for IBD. Professor Peyrin-Biroulet is a co-founder of the Spectrum consortium and President of the IBD Cancer and Serious Infections in Europe (I-CARE) project. He also served as Councillor to the Immunology, Microbiology and IBD section of the American Gastroenterological Association (AGA) Institute Council (2014–2016).

Professor Peyrin-Biroulet was an associate editor of Digestive Liver Diseases (2013–2017) and is a member of the editorial board of Alimentary Pharmacology & Therapeutics, Journal of Crohn’s and Colitis, Expert Review of Clinical Immunology and Gut. He has been an associate editor of Clinical Gastroenterology and Hepatology since 2017. Professor Peyrin-Biroulet also serves as a reviewer for several international journals and is a staff contributor to the Selected Summary section of Gastroenterology. He joined the editorial team of the Cochrane Inflammatory Bowel Diseases and Functional Bowel Disorders (IBD/FBD) Review Group in 2014.

Professor Peyrin-Biroulet received a rising star award in 2008 from UEGF. He is an author of more than 600 peer-reviewed articles and more than 200 non peer-reviewed articles.

Silvio Danese, MD PhD

Full Professor of Gastroenterology

Humanitas Research Hospital, Milan, Italy

Silvio Danese is the Head of the Inflammatory Bowel Disease (IBD) Research Unit in the Division of Gastroenterology at the Humanitas Research Hospital in Milan, Italy, as well as a professor of gastroenterology at Hunimed University in Milan.

Professor Danese trained in gastroenterology at Policlinico Gemelli, Rome, Italy and graduated with a PhD, working from 2001 to 2004 in Dr Claudio Fiocchi’s laboratory at the Case Western Reserve University, Cleveland, OH, USA. His main research area of interest is the investigation of the fundamental mechanisms underlying IBD pathogenesis, while his daily clinical activity is related to IBD service for IBD patients.

Professor Danese is actively involved in many international clinical trials in IBD, is a reviewer for many journals and has previously served as an associate editor for the World Journal of Gastroenterology. He is also a member of many organisations related to the IBD field, including the European Crohn’s and Colitis Organisation (ECCO), of which he became the President in February 2018.

Professor Danese has published more than 900 papers in several journals, including New England Journal of Medicine, Lancet, Gastroenterology, Gut and Journal of Clinical Investigation. Additionally, he has published more than 800 abstracts and related presentations at both national and international meetings.

Jean-Frederic Colombel, MD

Professor of Medicine

Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and the Leona M. and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Jean-Frederic Colombel has been the director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center since January 2013, where with colleagues he has built an “IBD Home”. Here, patients can benefit from the most advanced and coordinated care, including access to inflammatory bowel disease (IBD) specialists, surgeons, psychologists, nutritionists, pharmacists, social workers and affiliated health professionals.

Professor Colombel began his career at Centre Hospitalier Universitaire de Lille, France in 1980 where he was Professor of Hepato-Gastroenterology from 1991 and Head of the Department of Gastroenterology from 2010 to 2012. Since 1984, his research has focused on IBD. Thanks to the development of multiple local, national and international collaborations, he has been able to contribute to important advances in the pathophysiology of IBD.

Professor Colombel has trained several generations of Fellows both in the US and in Europe, and many of them are now key opinion leaders in IBD in their respective countries. This leadership in IBD has been recognised and he was elected as the President of the European Crohn’s and Colitis Organisation (ECCO) (2008–2010) and Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) (2010–2012). Professor Colombel was awarded the United European Gastroenterology Federation (UEGF) Research Prize in 2009 and the Crohn’s and Colitis Foundation (CCF) Clinical Research Award in 2014.

The main concretisation of Professor Colombel’s work has been the publication as primary author or co-author of more than 900 peer-reviewed papers, most of them in the domain of IBD, which has made him one of the most published gastroenterologists in the world. Professor Colombel has been an associate editor of major gastroenterology journals including Gut, Alimentary Pharmacology and Therapeutics and Gastroenterology (current).

  • Welcome and introductions
  • Ulcerative colitis: Today (plenary presentation)
    Professor Jean-Frederic Colombel, Icahn School of Medicine at Mount Sinai, NY, US
  • Ulcerative colitis: Tomorrow (plenary presentation)
    Professor Silvio Danese, Humanitas University, Milan, IT
  • Ulcerative colitis: The Future (plenary presentation)
    Professor Laurent Peyrin-Biroulet, Nancy University Hospital Vandoeuvre-lès-Nancy, FR
  • Hot topics discussion and close (interactive discussion via live Q&A chat)
    Professors Peyrin-Biroulet, Colombel and Danese

This symposium is not affiliated with UEG

Sign up to receive updates

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos N.V. © 2020 Galapagos N.V. All rights reserved.